These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20040339)

  • 1. Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.
    Karim A; Covington P; Christopher R; Davenport M; Fleck P; Li X; Wann E; Mekki Q
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):46-58. PubMed ID: 20040339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
    Dudkowski C; Tsai M; Liu J; Zhao Z; Schmidt E; Xie J
    Eur J Clin Pharmacol; 2017 Mar; 73(3):279-288. PubMed ID: 27999883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
    Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.
    Graefe-Mody EU; Padula S; Ring A; Withopf B; Dugi KA
    Curr Med Res Opin; 2009 Aug; 25(8):1963-72. PubMed ID: 19552619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients.
    Li J; Klemm K; O'Farrell AM; Guler HP; Cherrington JM; Schwartz S; Boyea T
    Curr Med Res Opin; 2010 Aug; 26(8):2003-10. PubMed ID: 20583949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
    Boulton DW; Smith CH; Li L; Huang J; Tang A; LaCreta FP
    Clin Drug Investig; 2011; 31(9):619-30. PubMed ID: 21819160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus.
    Chen XW; He ZX; Zhou ZW; Yang T; Zhang X; Yang YX; Duan W; Zhou SF
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1225-38. PubMed ID: 26218204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.
    Ndefo UA; Okoli O; Erowele G
    Am J Health Syst Pharm; 2014 Jan; 71(2):103-9. PubMed ID: 24375601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.
    Karim A; Laurent A; Munsaka M; Wann E; Fleck P; Mekki Q
    J Clin Pharmacol; 2009 Oct; 49(10):1210-9. PubMed ID: 19622714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
    Zhu Y; Statkevich P; Cutler DL
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):539-47. PubMed ID: 17966839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
    Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
    Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
    Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.
    Agrawal R; Bahare RS; Jain P; Dikshit SN; Ganguly S
    Mini Rev Med Chem; 2012 Nov; 12(13):1345-58. PubMed ID: 22512582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):1005-20. PubMed ID: 25936384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects.
    Graefe-Mody U; Giessmann T; Ring A; Iovino M; Woerle HJ
    Clin Ther; 2011 Aug; 33(8):1096-103. PubMed ID: 21803422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.